Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,110.00    -60.00 (-2.76%)
Bid:
2,114.00
Ask:
2,122.00
Spread: 8.00 (0.378%)
Market Cap: £1.40b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

AGM and Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6077Q
Genus PLC
08 November 2012
 



For immediate release

8 November 2012

 

 

Genus plc

('Genus' or 'the Company')

Annual General Meeting ('AGM') and Interim Management Statement

 

At the AGM of Genus to be held at 11.00am today, the following interim management statement will be made for the trading period from 1 July to 31 October 2012.

 

Current Trading

Following last year's record results, revenues for the four months to 31 October 2012 were slightly ahead of the strong performance achieved in the same period last year. Operating profits were lower than the same period last year driven by higher feed costs in our genetic nucleus farms and by delayed sales in Genus ABS caused by adverse weather conditions in Latin America.

 

The overall results have benefited from solid performances in Genus PIC and Genus Asia. In addition the strength of the Genus business model has limited the financial effect on Genus of the higher feed costs that are affecting many of our customers.

 

Genus PIC, comprising the porcine operations in North America, Latin America and Europe, achieved continued volume growth across all three regions. Operating profits were at a similar level to last year despite higher feed costs in our nucleus farm operations and planned increased investment in product development. Performance has benefited from continued growth in the CBV Plus and CBV Max programmes in North America and volume growth in Latin America. Europe has performed ahead of last year reflecting the start of restructuring benefits and the strengthening European porcine market.

 

Genus ABS, comprising the dairy and AI beef businesses in North America, Latin America and Europe, had a slow start to the year. Volumes were lower in Latin America where adverse weather conditions in Argentina and Brazil have caused a delay in semen sales. We expect these sales to be recovered as the year progresses. Performance in North America and Europe was slightly ahead of last year.

 

Genus Asia has had a good start to the year. Revenues and profits were in line with the strong performance achieved in the same period last year.

 

As expected finance costs were higher than last year, reflecting the previously indicated increase in pension interest costs following the additional pension provision made at 30 June 2012.

 

Financial Position

Net debt at the end of October 2012 was at a similar level to end June 2012 and well below the same time last year.

 

Strategy

We have made a good start in implementing our strategy to accelerate the rate of profit growth from 2014 onwards.

 

Following the implementation of a new market-place oriented organisation structure in July 2012, we are establishing global technical services, global marketing and a global supply chain for each of our porcine and dairy/AI beef businesses. This is already starting to create opportunities to enhance customer service which is a key element of our overall growth strategy.

 

In line with our strategy, we have appointed Saskia Korink Romani to the new position of Chief Marketing Officer. Saskia, who joins in January 2013, brings significant international business and marketing experience having worked for 10 years at Cargill, most recently as Vice President of Marketing, Animal Nutrition Division.

 

In Asia, key personnel appointments have been made as part of our plans to ensure we have the right resources in place to meet our growth aspirations.

 

In China, the initial stocking of the Besun porcine joint venture farm has been completed as planned and discussions with other potential joint venture partners are progressing.

 

Outlook

We expect to see a gradual improvement in performance as the year progresses particularly after the slow start in our Genus ABS business. We believe Genus remains on course to achieve another year of growth.

 

With the investments being made in the current year, particularly in emerging markets such as China and in core competencies such as marketing, technical services and product development, the Group is well placed to take advantage of the long-term opportunities available in the global animal genetics market.

 

 

For further information please contact:-

 

Genus plc: Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

 

Buchanan: Tel: 0207 466 5000

Charles Ryland

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus' customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBUURURAARUA
Date   Source Headline
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSTotal Voting Rights
31st Jan 20132:00 pmRNSBlocklisting Interim Review
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker
31st Jul 20122:00 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.